Nature Communications (Sep 2021)
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19
- Jiandong Huo,
- Halina Mikolajek,
- Audrey Le Bas,
- Jordan J. Clark,
- Parul Sharma,
- Anja Kipar,
- Joshua Dormon,
- Chelsea Norman,
- Miriam Weckener,
- Daniel K. Clare,
- Peter J. Harrison,
- Julia A. Tree,
- Karen R. Buttigieg,
- Francisco J. Salguero,
- Robert Watson,
- Daniel Knott,
- Oliver Carnell,
- Didier Ngabo,
- Michael J. Elmore,
- Susan Fotheringham,
- Adam Harding,
- Lucile Moynié,
- Philip N. Ward,
- Maud Dumoux,
- Tessa Prince,
- Yper Hall,
- Julian A. Hiscox,
- Andrew Owen,
- William James,
- Miles W. Carroll,
- James P. Stewart,
- James H. Naismith,
- Raymond J. Owens
Affiliations
- Jiandong Huo
- Structural Biology, The Rosalind Franklin Institute, Harwell Science Campus
- Halina Mikolajek
- Diamond Light Source Ltd, Harwell Science Campus
- Audrey Le Bas
- Structural Biology, The Rosalind Franklin Institute, Harwell Science Campus
- Jordan J. Clark
- Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool
- Parul Sharma
- Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool
- Anja Kipar
- Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool
- Joshua Dormon
- Structural Biology, The Rosalind Franklin Institute, Harwell Science Campus
- Chelsea Norman
- Structural Biology, The Rosalind Franklin Institute, Harwell Science Campus
- Miriam Weckener
- Structural Biology, The Rosalind Franklin Institute, Harwell Science Campus
- Daniel K. Clare
- Diamond Light Source Ltd, Harwell Science Campus
- Peter J. Harrison
- Protein Production UK, The Rosalind Franklin Institute – Diamond Light Source, The Research Complex at Harwell, Science Campus
- Julia A. Tree
- National Infection Service, Public Health England, Porton Down
- Karen R. Buttigieg
- National Infection Service, Public Health England, Porton Down
- Francisco J. Salguero
- National Infection Service, Public Health England, Porton Down
- Robert Watson
- National Infection Service, Public Health England, Porton Down
- Daniel Knott
- National Infection Service, Public Health England, Porton Down
- Oliver Carnell
- National Infection Service, Public Health England, Porton Down
- Didier Ngabo
- National Infection Service, Public Health England, Porton Down
- Michael J. Elmore
- National Infection Service, Public Health England, Porton Down
- Susan Fotheringham
- National Infection Service, Public Health England, Porton Down
- Adam Harding
- Sir William Dunn School of Pathology, University of Oxford
- Lucile Moynié
- Structural Biology, The Rosalind Franklin Institute, Harwell Science Campus
- Philip N. Ward
- Division of Structural Biology, The Wellcome Centre for Human Genetics, University of Oxford
- Maud Dumoux
- Structural Biology, The Rosalind Franklin Institute, Harwell Science Campus
- Tessa Prince
- Diamond Light Source Ltd, Harwell Science Campus
- Yper Hall
- National Infection Service, Public Health England, Porton Down
- Julian A. Hiscox
- Diamond Light Source Ltd, Harwell Science Campus
- Andrew Owen
- Department of Pharmacology and Therapeutics, Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool
- William James
- Sir William Dunn School of Pathology, University of Oxford
- Miles W. Carroll
- National Infection Service, Public Health England, Porton Down
- James P. Stewart
- Diamond Light Source Ltd, Harwell Science Campus
- James H. Naismith
- Structural Biology, The Rosalind Franklin Institute, Harwell Science Campus
- Raymond J. Owens
- Structural Biology, The Rosalind Franklin Institute, Harwell Science Campus
- DOI
- https://doi.org/10.1038/s41467-021-25480-z
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 18
Abstract
Neutralizing nanobodies (Nb) are of considerable interest as therapeutic agents for COVID-19 treatment. Here, the authors functionally and structurally characterize Nbs that bind with high affinity to the receptor binding domain of the SARS-CoV-2 spike protein and show that an engineered homotrimeric Nb prevents disease progression in a Syrian hamster model of COVID-19 when administered intranasally.
